Best-Selling Cancer Drugs, Top 10 Best-Selling Cancer Drugs, Q1–Q3, 2017 Source: GEN – Genetic Engineering & Biotechnology News 10.11.2018 г.

Top 10 Best-Selling Cancer Drugs, Q1–Q3 2017 Trade Name/INN Indication Q1–Q3 sales 2017 Q1–Q3 sales 2016 % Change  1. Revlimid® (lenalidomide) Multiple myeloma, in combination with dexamethasone; multiple myeloma, as a maintenance therapy following autologous hematopoietic stem cell transplantation; transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities; mantle cell lymphoma in patients whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. $5.999 billion $5.166 billion  16, 1 % 2. Rituxan® (rituximab, MabThera)  Non-Hodgkin lymphoma; chronic lymphocytic leukemia; rheumatoid arthritis (RA) in combination with methotrexate in adult patients with moderately to severely active RA who have inadequate response to one or more TNF-antagonist therapies; granulomatosis with polyangiitis (GPA) (Wegener’s granulomatosis), and microscopic polyangiitis (MPA) in adults in combination with glucocorticoids $5.760 billion $5.620 billion 2.5% 3. Herceptin (trastuzumab) HER2-overexpressing breast cancer; HER2-overexpressing metastatic gastric or gastroesophageal-junction adenocarcinoma $5.363 billion $5.252 billion 2.1% 4. Avastin (bevacizumab) Metastatic colorectal cancer, nonsquamous non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, cervical cancer, as well as recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer $5.121 billion $5.241 billion -2.3% 10.11.2018 г.

Top 10 Best-Selling Cancer Drugs, Q1–Q3 2017 (2) Trade Name/INN Indication Q1–Q3 sales 2017 Q1–Q3 sales 2016 % Change 5. Neulasta/Peglasta (pegfilgrastim) and Neupogen/Gran (filgrastim) Both Neulasta and Neupogen decrease the incidence of infection—as manifested by febrile neutropenia—in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia; and increase survival in patients acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome or acute radiation syndrome). $3.864 billion, consisting of $3.420 billion for Neulasta (Amgen), $423 million for Neupogen (Amgen), and ¥2.4 billion ($21.203 million) combined (Kyowa Hakko Kirin) $4.151 billion, consisting of $3.532 billion for Neulasta (Amgen), $592 million for Neupogen (Amgen), and ¥3.1 billion ($27.388 million) combined (Kyowa Hakko Kirin) -6.9% 6. Opdivo (nivolumab) Melanoma, metastatic non-small cell lung cancer (NSCLC), advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, colorectal cancer, and hepatocellular carcinoma $3.587 billion $2.464 billion 45.6% 7. Imbruvica® (ibrutinib) Adults with mantle cell lymphoma who have received at least one prior therapy; chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); CLL/SLL with 17p deletion; Waldenström’s macroglobulinemia; Marginal zone lymphoma who require systemic therapy and have received at least one prior anti-CD20-based therapy; Chronic graft-versus-host disease after failure of one or more lines of systemic therapy $3.236 billion $2.226 billion 45.4% 8. Keytruda® (pembrolizumab) Melanoma, non-small cell lung cancer, head and neck squamous cell cancer, classical Hodgkin Lymphoma, urothelial carcinoma, microsatellite instability-high cancer, and gastric cancer $2.512 billion $919 million 173.3%

Top 10 Best-Selling Cancer Drugs, Q1–Q3 2017 (3) Trade Name/INN Indication Q1–Q3 sales 2017 Q1–Q3 sales 2016 % Change 9. Ibrance® (palbociclib) Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women; or fulvestrant in women with disease progression following endocrine therapy $2.410 billion $1.492 billion 61.5% 10. Velcade® (bortezomib) Multiple myeloma, mantle cell lymphoma $1.780 billion $1.876 billion -5.1%